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Glycolysis-driven Growth in 
Drosophila Tumors
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Tumors frequently fail to pass on all their chromosomes correctly during cell division, and this 
chromosomal instability (CIN) causes irregular aneuploidy and oxidative stress in cancer cells. Our 
objective was to test knockdowns of metabolic enzymes in Drosophila to find interventions that 
could exploit the differences between normal and CIN cells to block CIN tumor growth without 
harming the host animal. We found that depleting by RNAi or feeding the host inhibitors against 
phosphoenolpyruvate carboxykinase (PEPCK) was able to block the growth of CIN tissue in a brat 
tumor explant model. Increasing NAD+ or oxidising cytoplasmic NADH was able to rescue the growth 
of PEPCK depleted tumors, suggesting a problem in clearing cytoplasmic NADH. Consistent with this, 
blocking the glycerol-3-phosphate shuttle blocked tumor growth, as well as lowering ROS levels. This 
work suggests that proliferating CIN cells are particularly vulnerable to inhibition of PEPCK, or its 
metabolic network, because of their compromised redox status.
Chromosomal instability (CIN) refers to cell divisions that cannot maintain chromosomal integrity or number. 
This can be caused by defects including elevated DNA damage, weakened cell cycle checkpoints or an aberrant 
mitotic spindle1. CIN is a common phenotype of human tumours and generates genetic variation that has been 
associated with tumour evolution, the development of drug resistance and the consequent poor prognosis of CIN 
cancer patients2. We and others have proposed that CIN itself could be an attractive target for chemotherapy, as 
it is a relatively cancer-specific phenotype 3–6. However, as CIN cells are necessarily genetically diverse, it is chal-
lenging to identify conserved features of CIN cells as potential targets. Our approach has been to induce CIN in 
a genetically uniform population of cells in vivo in Drosophila and to screen for genes that can be knocked down 
to kill CIN cells without affecting normal proliferating cells3, 7, 8. We hypothesize that the candidates giving wide-
spread cell death in CIN cell populations are targeting vulnerabilities common to a wide range of aneuploidies.
This approach identified plausible targets such as JNK signalling and centrosomal regulators that could be 
depleted to give CIN-specific lethality3. In addition, we found metabolic targets such as Phosphoenol pyruvate 
carboxykinase (PEPCK), and Glucose-6-phosphate dehydrogenase (G6PD)7. Knockdown of these genes gave 
increased mitochondrial output, reactive oxygen species (ROS), DNA damage and cell death in CIN cells without 
affecting normal proliferating cells. Tumours are often metabolically unlike their surroundings, with elevated 
glycolysis for anabolism rather than ATP generation9. This metabolic demand is shared to some extent by all 
proliferating cells, as they must generate cellular building blocks before they can replicate their DNA and divide. 
CIN tumours carry an additional burden, however, as it has been observed that aneuploid cells suffer redox stress 
in proportion to their aneuploidy10. Though we lack a detailed understanding of how aneuploidy causes redox 
stress, the evidence implicates a combination of elevated ROS levels and protein turnover problems11. The com-
bination of this redox stress and a Warburg metabolism makes CIN tumours potentially vulnerable to metabolic 
intervention that does not affect normal cells.
Having found metabolic targets that were able to kill proliferating cells with induced CIN, we wished to under-
stand their mechanism of action in the context of a growing CIN tumour. In this paper we describe the CIN 
status of brat explant tumours and their use as a fly CIN tumour model. Chemical as well as genetic inhibition of 
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Figure 1. Characterization of brat-RNAi as a CIN tumor model. (a) RFP-labelled 3rd instar larval brain tissue 
depleted for Brat (da > Gal4; UAS-RFP; UAS-brat-RNAi) was dissected and transplanted into the abdomen of 
wild type adult hosts. Serial passages of the tumor explant were carried out into a new host within a fortnight 
to allow the tumor growth to be continued. (b) Control 3rd instar larval brain tissue (da > Gal4; UAS-RFP) was 
transplanted and showed no growth after 2 (b) or 14 days (b’). Labelled 3rd instar larval brain tissue explants 
depleted for Brat (da > Gal4; UAS-RFP; UAS-brat-RNAi) showed considerable growth on day 13 (c) compared 
to day 2 (c) after transplantation. (d) The average growth rate of brat tumor explants (da > Gal4; UAS-RFP; 
UAS-brat-RNAi). A significant decrease in the mean growth rate was observed in Passage 2 (p < 0.01, n = 19) 
and Passage 3 (p < 0.001, n = 8) relative to the first transplantation. (e) Cell death was measured in 3rd instar 
larval brains depleted for Brat (da > Gal4; UAS-RFP; UAS-brat-RNAi) and in serial passages of this tissue. The 
rate of cell death significantly increased in the second and third passage (p < 0.001, n > 13 for each), but was 
not significantly different from the larval tissue to the first explant (p > 0.06, n > 13). (f) The level of reactive 
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metabolic candidates in this model identified targets such as PEPCK that could effectively block tumour growth. 
Elevated levels of ROS were observed in the targeted tissue, and adding antioxidants could rescue growth. 
Experiments to identify the source of the ROS suggested that pressure to clear cytoplasmic NADH generated in 
glycolysis was leading to ROS generation by the glycerol phosphate shuttle. Our results suggest that metabolic 
interventions that constrain clearance of NADH can generate toxic ROS levels in CIN tumours without harming 
the host.
Results
Characterization of bratRNAi as a CIN tumor model. Mutations in the gene brain tumour (brat) cause 
tumours in Drosophila larval brains due to a failure of neuroblast differentiation12, and this tissue can be grown 
indefinitely as explant tumors if serially transplanted into the abdomen of host adult flies13 (Fig. 1a). We initially 
tested whether depletion of Brat by RNAi gave effective tumour growth comparable to mutant alleles. Dissection 
of third instar larval brains from control animals marked with RFP and transplanted in to a wild type adult 
host showed no growth (Fig. 1b), but depletion of Brat by RNAi resulted in strong growth of the RFP-tagged 
transplanted tissue (Fig. 1c) that would typically kill the host within two weeks. Serial passaging of the tumor 
tissue after ten days’ growth allowed the development of the tumors to be followed. We observed a significant 
decrease in the rate of growth (Fig. 1d) and increased cell death (Fig. 1e) in these tumors over the first three 
passages. Levels of reactive oxygen species (ROS) were high in the explants, with a significant increase relative 
to the larval brain tumour and from the first to third passage (Fig. 1f). We also observed metastasis, which is a 
common feature of these explant tumors14. Measuring the frequency of aberrant anaphases showed that the CIN 
rate was 20.2% (±3.2%) in bratRNAi larval brains (n = 15), comparable to our previous CIN model, mad2RNAi, 
which showed defects in 24% of anaphases3. We further analysed the CIN rate in bratRNAi tumor explants up to 
three passages and found the highest CIN rate in passage 1 which decreased over time in the subsequent passages, 
similar to the explant growth rate (Fig. 1g). These initial studies confirmed that depletion of brat by RNAi was 
a viable method for generating aggressive CIN tumors that shared the high-ROS phenotype that we and others 
identified when CIN was induced in normal proliferating tissue7, 15, 16.
Effect of metabolic interventions on CIN tumors. Having previously shown that cells with induced 
CIN are sensitive to several metabolic interventions7, we now wished to test the effect of such knockdowns on 
CIN tumors. We tested a range of genes affecting glucose usage (G6PD, PEPCK, Wwox), lipid metabolism (Mfe2) 
and antioxidant responses (JNK). We initially measured their effect on the size of overgrowth observed in bratRNAi 
larval brains (Fig. 2a). All of the candidate knockdowns tested gave significantly reduced overgrowth at this stage, 
with some no larger than non-tumorous controls (e.g. bratRNAiJNKRNAi). Reduced overgrowth could have been 
caused by less proliferation or more cell death; our data from wing discs suggested that cell death was likely to be 
occurring7. Surprisingly, we did not observe a significant increase in cell death relative to brat alone for any of the 
candidate knockdowns except Glucose-6-phosphate dehydrogenase (G6PD; Fig. 2b). Elevated CIN rates can also 
impact proliferation, so we tested whether the knockdown of the candidates was affecting the incidence of CIN in 
brat larval brains. Depletion of Jun N-terminal kinase (JNK) gave a significant increase in the CIN rate, while the 
others had little (Mfe2) or no effect (Fig. 2c). These data indicated that all of the candidates were able to impact the 
growth of brat larval brains, and suggested that varied mechanisms were responsible, with G6PD depletion giving 
cell death and JNK depletion causing more CIN. When these candidates were tested for their effect on ongoing 
tumor proliferation in explants, we were surprised to find that neither G6PD nor JNK depletion were able to 
effectively inhibit brat tumor growth (Fig. 2d). However, depletion of either Phosphoenolpyruvate Carboxykinase 
(PEPCK) or Multifunctional enzyme type 2 (Mfe2) did block the growth of explanted brat tumors (Figs 2d and 3).
The role of NADH in brat tumour growth inhibition by PEPCK depletion. As an enzyme with a 
relatively well characterized function in glucose metabolism, PEPCK became the focus of further investigation 
aimed at explaining how CIN tumor growth can be blocked. We found that feeding the hosts an inhibitor to 
PEPCK (hydrazine; Hyd) was able to block brat explant growth, consistent with our depletion of PEPCK in the 
tumor by RNAi (Fig. 3). PEPCK catalyses the inter-conversion of oxaloacetate and phosphoenolpyruvate (Fig. 4a) 
and is rate limiting for gluco- and glyceroneogenesis17, 18. Proliferating cells must generate lipids and nucleotides, 
and to do so typically drive glycolysis at a high rate. This leads to a build-up of NADH in the cytoplasm which 
must be cleared for glycolysis to continue. The glycerol-3-phosphate shuttle is an important sink for NADH that 
could be significant for the growth of brat tumors19. PEPCK is required for glyceroneogenesis (Fig. 4a), which is 
oxygen species (ROS), was measured in labelled 3rd instar larval brains depleted for Brat (da > Gal4; UAS-RFP; 
UAS-brat-RNAi), and compared with subsequent serial passages of the explanted tissue (P1 to P3) or with 
tissue treated with an antioxidant (EGCG) or pro-oxidant (Mnd; Menadione) as controls. A strong increase in 
ROS was observed in the first passage (p < 0.001, n = 10), with a modest increase from passage 1 to passage 3 
(p < 0.05, n = 16). (g) The rate of chromosomal instability was measured in larval brains (da > Gal4; UAS-RFP; 
UAS-brat-RNAi) and subsequent passages of this explanted tissue. The proportion of visibly aberrant anaphase 
figures was significantly higher in the first passage (78 ± 3%, n = 141 compared to 20 ± 3%, n = 622, p < 0.001), 
but then decreased over the next two passages (p < 0.001, n > 100 for each). (h,i) Representative images of 
normal and defective anaphases from Brat depleted brain tissue (da > Gal4; UAS-RFP; UAS-brat-RNAi), 
quantitated in (g). The arrow indicates an anaphase bridge. In all graphs, error bars show the 95% confidence 
intervals. Variation in means were tested for significance using Dunnett’s multiple comparisons test. Variation 
in proportions were tested for significance using Fisher’s exact tests.
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a significant contributor to the generation of glycerol-3-phosphate, even in the presence of glucose20. We tested 
the requirement for this shuttle by either depleting cytoplasmic Glycerol-3-Phosphate Dehydrogenase (Gpdh) 
in the tumour or by feeding the host a specific inhibitor (iGP1) of GPO1, the mitochondrial Glycerophosphate 
Figure 2. Identifying gene knockdowns that affect CIN tumor growth. (a). Comparison of the size of 3rd instar 
larval brains depleted for Brat (da > Gal4; UAS-RFP; UAS-brat-RNAi) or brat and one of five genes known to 
increase apoptosis in CIN cells. Control brains were da > Gal4; UAS-RFP. Error bars indicate 95% confidence 
intervals, n > 10 in all cases. All candidate gene knockdowns gave a significant reduction in larval brain size 
relative to brat-RNAi alone (p < 0.001 for all except Wwox-RNAi, p < 0.05). (b) Apoptosis in brat-RNAi larval 
brains was compared with brat plus candidate knockdowns. Depletion of G6PD showed significantly elevated 
apoptosis compared to the brat alone control (p < 0.001, n ≥10). All other comparisons with the control showed 
no significant variation (p > 0.05). (c) The rate of chromosomal instability was measured in larval brains depleted 
for Brat (da > Gal4; UAS-RFP; UAS-brat-RNAi) and compared with brains lacking Brat and a candidate. The 
proportion of aberrant anaphases was elevated relative to the brat control (20%, n = 622 anaphases) when JNK 
(56%, p < 0.001, n = 495) or Mfe2 (32%, p < 0.05, n = 257) were also depleted. All other comparisons with the brat 
control showed no significant variation (p > 0.05 using Fisher’s exact test, n > 200 for each). (d) Growth rate of 
tumor explants. RFP labelled brain tissue from 3rd instar larvae was transplanted into a wild type adult host and 
growth was measured over two weeks. No growth was observed in control tissue (da > Gal4; UAS-RFP). Depletion 
of Brat led to rapid explant growth, which was not significantly affected by co-depleting G6PD, JNK or Wwox 
(p > 0.05, n ≥ 10). Co-depletion of PEPCK gave a strongly reduced growth rate relative to brat alone (p < 0.05, 
n = 10), as did co-depleting Mfe2 (p < 0.05, n = 10). All error bars show the 95% confidence interval, p values are 
from Dunnett’s multiple comparisons test except for proportions, for which Fisher’s exact test was used.
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Figure 3. Effect of metabolic intervention on the growth of CIN tumors. (a) Labelled 3rd instar brain tissue 
depleted for Brat (actin > Gal4; UAS-RFP; UAS-brat-RNAi) was grown in wild type hosts for up to two 
weeks. Feeding the host with the PEPCK inhibitor Hydrazine (Hyd.) blocked tumor growth, as did depleting 
PEPCK by RNAi. Co-depletion of the cytoplasmic Glycerol-3-Phosphate Dehydrogenase (Gpdh), Malate 
dehydrogenase (Mdh1) or Malic Enzyme (Men) with Brat was able to block growth, as did feeding the host 
iGP1 to inhibit the mitochondrial Glycerophosphate Oxidase. All treatments gave a statistically significant 
decrease in growth relative to the brat control (p < 0.001 for each, n ≥ 5) (b) The effect of supplementing food 
with nicotinamide (Nam) was tested on host adults carrying explanted tumors with the indicated genotypes. 
All genotypes showed significantly increased explant growth when given nicotinamide (multiple t-tests using 
the Holm-Sidak method, *p < 0.05, **p < 0.01, ***p < 0.001). (c) Explants depleted for Brat and PEPCK 
(actin > Gal4; UAS-RFP; UAS-brat-RNAi; UAS-PEPCK-RNAi) did not grow, but could be induced to grow by 
feeding their adult hosts the antioxidant propyl gallate (PG). Increasing the NAD+/NADH ratio by feeding the 
hosts ferricyanide (FeCN) or nicotinamide (Nam) could also rescue the explant growth. Significant increases 
over the brat PEPCK control (n = 18) were seen for PG and Nam (p < 0.001, n = 8 and 28), with a modest 
increase seen for FeCN (p < 0.05 by one-tailed t-test, n = 13). (d) The effect of NADH on cell death seen in 
non-tumorous CIN cells depleted for PEPCK. Cells in the posterior half of 3rd instar larval wing discs depleted 
for mad2 and PEPCK (en > Gal4; UAS-CD8-GFP; UAS-mad2-RNAi; UAS-PEPCK-RNAi) show a high rate of 
cell death, as measured by Acridine Orange incorporation7, relative to the wild type cells in the anterior half 
of each disc. The mad2 alone control (en > Gal4; UAS-CD8-GFP; UAS-mad2-RNAi; UAS-LacZ-RNAi) shows 
little signal. Increasing the NAD+/NADH ratio by feeding with either ferricyanide (FeCN) or nicotinamide 
(Nam) significantly decreased the level of cell death (p < 0.001 for both, n ≥ 10). (e) The effect of inhibiting the 
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Oxidase19. In either case, the growth of brat explants was blocked (Fig. 3a). We were not able to block growth by 
inhibiting hexokinase or uncoupling mitochondrial respiration (data not shown). The inhibition of tumor growth 
by blocking the glycerol phosphate shuttle suggested that these tumors may be sensitive to cytoplasmic NADH 
build-up.
Replacing NAD + can rescue PEPCK brat explant growth. This model for the role of NADH in medi-
ating the effect of PEPCK on brat tumor explants would predict that providing the tumor with NAD+ should 
bypass the need for PEPCK, allowing glycolysis to proceed and PEPCK brat explants to grow. We tested this 
model by feeding the host adult nicotinamide (Nam), a precursor in the synthesis of NAD+ 21. While brat tum-
ors depleted for PEPCK did not grow, we found that the same tumors in hosts fed nicotinamide were able to 
grow, albeit slowly (Fig. 3b). This strongly suggested that lack of NAD+ was a limiting factor when PEPCK was 
depleted. We also found that nicotinamide rescued the growth of brat tumors lacking Gpdh (Fig. 3b), confirming 
the importance of the glycerol-3-phosphate shuttle in oxidising NADH in these tumors. Ideally we would have 
confirmed this by measuring cytoplasmic NAD+/NADH ratios in the explants, but the low NADH concentration 
combined with tiny tissue size made this technically problematic. As an alternative approach, we confirmed that 
cytoplasmic NADH was growth limiting in PEPCK depleted tumors by feeding the hosts ferricyanide (FeCN)22 
which externally drives NADH oxidation, and this was also able to increase growth (Fig. 3c). To test whether this 
rescue of PEPCK phenotypes by NADH oxidation was a feature only of brat tumors, we tested non-tumorous 
proliferating cells in which CIN had been induced by Mad2 depletion. The level of cell death and ROS induced 
by PEPCK depletion in this CIN tissue was significantly rescued by feeding the larvae either ferricyanide or nic-
otinamide (Figs 3d and 5). Proliferating wing disc tissue in which CIN was induced by BubR1 depletion showed 
similar sensitivity to PEPCK depletion (Supplementary Figure 2).
An important side-effect of using the glycerol-3-phosphate shuttle is the production of ROS by mitochon-
drial Glycerophosphate Oxidase (GPO1)23, 24. Given that we observed high levels of ROS in brat tumor explants 
(Fig. 1f), we wished to test whether ROS levels were limiting the usefulness of the glycerol-3-phosphate shuttle 
when PEPCK was depleted. When adult hosts were fed with an antioxidant (propyl gallate; PG), we observed a 
significant rescue of the growth of PEPCK depleted brat tumor explants (Fig. 3c). We tested whether the antiox-
idant rescue seen with propyl gallate was affecting ROS generated by the glycerol phosphate shuttle, by feeding 
Brat depleted larvae metformin, which inhibits mitochondrial Glycerol-3-phosphate Dehydrogenase/GPO125 
(Fig. 3e). Increasing levels of metformin gave decreasing levels of ROS, consistent with the ROS in brat-RNAi 
brain tissue being generated by the glycerol-3-phosphate shuttle. Similarly, adding a specific inhibitor to the glyc-
erol phosphate shuttle in cells depleted for PEPCK and Mad2 also lowered ROS levels (Fig. 5f).
CIN tissues can have an elevated metabolic rate, consuming energy stores faster and producing more mito-
chondrial output than normal proliferating cells7. This was reflected in an increased rate of uptake of labelled 
glucose in proliferating CIN tissue (Rad21-RNAi) relative to controls (Fig. 3f). Feeding the animals a Gpo1 inhib-
itor to block the glycerol-3-phosphate shuttle significantly decreased the uptake of glucose (Fig. 3f), consistent 
with this shuttle being an important sink for NADH that allows glycolysis to continue at a high rate. Depletion 
of PEPCK did not strongly block glucose uptake (Supplementary Figure 3), however in brat tumors, depletion of 
PEPCK had a stronger effect (Fig. 4b), and could be rescued by feeding ferricyanide, confirming the importance 
of NADH oxidation for continued glycolysis in these tumors.
Discussion
CIN induced in Drosophila wing discs has reproducible phenotypic effects3–5, 15, 26, even though the genetic insta-
bility is effectively random. CIN cells typically generate reactive oxygen species, activate the p38 and JNK/Upd 
pathways, drop out of the epithelial layer and trigger an innate immune response. Because of this stereotypical 
response to induced aneuploidy, we reasoned that there should be ways to effectively target the response that 
should be specific to CIN cells. By screening for such CIN-killing interventions, we found several, such as tar-
geting JNK or centrosomes, that were effective but not ideal due to their important roles in normal proliferating 
cells3. Metabolic intervention, on the other hand, has better potential as a therapeutic tool because normal cells 
can tolerate large changes in metabolite concentrations, which they experience during feeding and fasting. On 
that basis we wished to further investigate the effect of metabolic intervention not just on epithelial cells with 
induced CIN, but on a CIN tumour growing in vivo.
Explanted Drosophila brain tumours have been used for over a decade13 and allow the development of a 
tumour to be followed for months by regular passaging. These tumours have been shown to accumulate additional 
glycerol-3-phosphate shuttle on reactive oxygen species produced in Brat depleted 3rd instar larval brain tissue 
(actin > Gal4; UAS-RFP; UAS-brat-RNAi). Adding Metformin at 10 mM or 25 mM significantly decreased 
the level of ROS observed in brat tissue (***p < 0.001, n ≥ 10; ns: p > 0.05). Menadione (Mnd.) and vitamin E 
(VitE) were used as control pro- and anti-oxidant treatments respectively. (f) The uptake of labelled glucose in 
CIN cells was decreased by blocking both PEPCK and the glycerol-3-phosphate shuttle. The posterior halves 
of 3rd instar larval wing discs were depleted for Rad21 (en > Gal4; UAS-CD8-GFP; UAS-Rad21-RNAi; UAS-
Dicer2) to induce CIN. This strongly increased the uptake of fluorescently labelled 2-NBD-Glucose. Depletion 
of PEPCK in CIN cells did not significantly decrease the rate of glucose uptake (p > 0.05, n = 25) relative to CIN 
alone (n = 18). Blocking the glycerol-3-phosphate shuttle by inhibiting GPO1 with iGP1 caused some decrease 
(p < 0.05, n = 12), while adding iGP to wings depleted for PEPCK strongly decreased the rate of glucose uptake 
(p < 0.001, n = 36). In all graphs, error bars show the 95% confidence interval. P values given are from Dunnett’s 
multiple comparisons tests unless otherwise noted.
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centrosomes and become aneuploid, so we were not surprised to find that the CIN rate in transplanted brat tissue 
was relatively high. We also observed an elevated level of reactive oxygen species, consistent with previous find-
ings from Drosophila cells with induced CIN7, 15 and from stable aneuploidy in a range of organisms27. Of course, 
brat tumours have other changes in addition to CIN28, but the phenotype of the brat tumours was sufficiently 
similar to our induced-CIN model to encourage us to examine the best metabolic candidates we had identified in 
the wing disc CIN model. Surprisingly, depleting proteins like G6PD or JNK had little effect on tumour explant 
growth (Fig. 2d), though they both strongly induced cell death in our wing disc model3. We considered whether 
the number of unstable divisions during the extended proliferation period available to the explants might have 
generated sufficient variation to allow the appearance of mutant clones resistant to the effect of our knockdowns. 
We think this unlikely, as other similar interventions, such as PEPCK-RNAi never acquired resistance and for 
G6PD or JNK we did not see a period of limited growth followed by rapid expansion, which would be expected 
if tumours were acquiring resistance. Instead we saw immediate growth upon transplantation, suggesting that in 
this environment, those knockdowns were not able to effectively block cell proliferation. Prior to transplantation, 
knockdown of G6PD did give reduced brain size and increased ROS and cell death in brat larval brains, suggest-
ing that some feature of the transplantation environment was able to rescue their growth. Further investigation 
will be needed to account for this growth difference.
Following our initial tests, we focused our attention on PEPCK, which consistently blocked the growth of 
explanted tumours. PEPCK is best known for its role in the liver, where it mediates gluconeogenesis during fast-
ing29. However, PEPCK is expressed widely in non-gluconeogenic tissue in most organisms, notably in muscle 
and gut as well as cancer cells, where its role is more complex, facilitating the catabolism of either glucose or 
glutamine30. PEPCK is regulated transcriptionally by p38 via ATF-231 and post-translationally by acetylation32. 
PEPCK is rate limiting for glyceroneogenesis, the synthesis of glycerol-3-phosphate from TCA cycle interme-
diates33. This is particularly important for the re-esterification of free fatty acids, which is needed to prevent 
the depletion of fats that we and others have noted when PEPCK is removed7, 34. Cell proliferation requires the 
doubling of membrane lipids at each division, so this demand for lipid synthesis could be an important role for 
PEPCK in non-gluconeogenic tissues. However, PEPCK null mutants and RNAi knockdowns remain viable3, 34, so 
this is insufficient to explain why PEPCK depleted brat explants cannot grow and why PEPCK depleted CIN wing 
disc cells apoptose. A possible explanation is suggested by our observation that providing antioxidants or increas-
ing NAD+ could rescue the growth of PEPCK depleted brat explants. Our data suggest that these interventions 
Figure 4. Model for the effect of PEPCK and NADH on glucose metabolism. (a) Proliferating cells require 
glucose for processes including the synthesis of nucleotides (via the pentose-phosphate pathway), membrane 
lipids (via pyruvate and citrate) and energy (via pyruvate or the glycerol-3-phosphate shuttle). Cytoplasmic 
NADH is produced in making phosphoenolpyruvate, which must be oxidised for glycolysis to continue. 
NADH can be oxidised by making lactate, but this prevents the use of pyruvate for lipid synthesis or energy. 
The glycerol-3-phosphate shuttle can oxidise NADH, but does so at the cost of generating elevated ROS levels. 
PEPCK mediates glyceroneogenesis (broad arrow), which uses citrate exported from mitochondria to generate 
glycerol-3-phosphate while oxidising NADH. Our model is that depletion of PEPCK decreases the levels of 
cytoplasmic NAD+ , which inhibits glycolysis unless the NAD+ can be regenerated by the glycerol-3-phosphate 
shuttle. This shuttle generates reactive oxygen species, so its use is limited in CIN cells which are already 
redox stressed. The inhibitors used to test this model are shown with their targets. Abbreviations: DHAP: 
dihydroxyacetone phosphate, Gpdh: Glycerol-3-phosphate Dehydrogenase, Gpo1: mitochondrial Glycerol-3-
Phosphate Dehydrogenase/Glycero-phosphate oxidase, iGP1: inhibitor of Glycerophosphate oxidase 1, Met: 
Metformin, Nam: nicotinamide, FeCN: ferricyanide, PEPCK: Phosphoenolpyruvate Carboxykinase. (b) The 
effect of PEPCK depletion on glucose uptake in brat depleted brain tissue. The uptake of fluorescently labelled 
2-NBD-glucose in 3rd instar larval brains was increased by the depletion of Brat (actin > Gal4; UAS-RFP; UAS-
brat-RNAi; p < 0.001, n ≥ 25). Depleting PEPCK in these brat tumors (actin > Gal4; UAS-RFP; UAS-brat-RNAi; 
UAS-PEPCK-RNAi) led to significantly lower uptake of labelled glucose (p < 0.001, n ≥ 25), which was rescued 
by feeding the larvae with ferricyanide (FeCN, p < 0.05, n ≥ 23). Error bars show 95% confidence intervals. 
Comparisons were done by multiple t-tests using Tukey’s method.
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affected the glycerol phosphate shuttle, which may be an important sink for the NADH generated during glycol-
ysis, but which also generates ROS23.
NADH is made from NAD+ in the cytoplasm during glycolysis, and must be oxidised for glycolysis to con-
tinue. Pyruvate can be converted to lactate to regenerate NAD+ , however this option is limited in proliferative 
cells as pyruvate is in demand for energy and lipid synthesis (Fig. 4a). In some organisms the Malate/Aspartate 
shuttle is used to lower levels of cytoplasmic NADH, however in Drosophila, the Mdh1 and Got1 enzymes that 
would catalyse the cytoplasmic half of the shuttle are found in peroxisomes35. Nonetheless, our data suggest Mdh1 
Figure 5. The effect of cytoplasmic NADH levels on the survival and metabolism of CIN cells depleted 
for PEPCK. (a–d) Cell death caused by depletion of Mad2 and PEPCK could be rescued by feeding larvae 
chemicals to alter cytoplasmic NADH levels. (a) Cells in the posterior half of 3rd instar larval wing discs (left 
of the dotted lines) were depleted for Mad2 and PEPCK (en > Gal4; UAS-CD8-GFP; UAS-mad2-RNAi; UAS-
PEPCK-RNAi) and showed an elevated level of cell death, as visualized by Acridine Orange7, relative to the 
wild type cells in the anterior half of each disc. Increasing the cytoplasmic NAD+/NADH ratio by feeding with 
either ferricyanide (d, FeCN) or nicotinamide (c, Nam) significantly decreased the level of Acridine staining, as 
did blocking the glycerol phosphate shuttle by feeding iGP1 (b). Quantitation of the rescue is shown in Fig. 3d. 
(e–h) ROS caused by depletion of Mad2 and PEPCK could also be rescued by changing NADH availability. 
(e) Cells in the posterior half of 3rd instar larval wing discs (left of the dotted lines) were depleted for Mad2 
and PEPCK (en > Gal4; UAS-CD8-GFP; UAS-mad2-RNAi; UAS-PEPCK-RNAi) and showed an elevated level 
of ROS, as visualized by CellRox, relative to the wild type cells in the anterior half of each disc. Increasing the 
cytoplasmic NAD+/NADH ratio by feeding with either 5 mM ferricyanide (h, FeCN) or 5 mM nicotinamide 
(g, Nam) decreased the level of CellRox staining, as did blocking the glycerol phosphate shuttle by feeding with 
2 μM iGP1 (f).
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is still needed to regulate NADH in CIN tumors (Fig. 3a,b). An effective alternative for oxidising cytoplasmic 
NADH is via the glycerol-phosphate shuttle. This shuttle uses Glycerol Phosphate Dehydrogenase to divert from 
glycolysis as much glyceraldehyde phosphate as required to oxidise NADH. This makes glycerol-3-phosphate, 
which can be removed by dephosphorylation to glycerol, or by acylation to make fats, however the shuttle uses 
mitochondrial Glycerophosphate Oxidase to generate energy in the mitochondria while recovering the glyc-
eraldehyde phosphate for glycolysis. This pathway is heavily used in muscle, but it can also generate signifi-
cant levels of ROS23. We found that the shuttle is important in proliferating CIN cells, as inhibiting or depleting 
Glycerophosphate Oxidase caused a significant decrease in glucose uptake, and blocked the growth of brat 
explants.
We found that increasing the availability of NAD+ by feeding the host nicotinamide rescued the growth of 
PEPCK depleted brat explants, suggesting that in these tumours, the glycerol phosphate shuttle has not been 
able to sufficiently oxidise NADH, despite the availability of glucose to fuel this pathway. One possible contrib-
utor to this limitation was the ROS generated by mitochondrial Glycerophosphate Oxidase (GPO1)23, because 
we know that cells with CIN are already redox stressed7. Consistent with this model (Fig. 4a), we found that 
inhibiting Glycerophosphate Oxidase lowered ROS levels but did not allow growth of brat explants (as the shuttle 
was then unavailable for NADH oxidation). However, lowering ROS by feeding the host antioxidants was able to 
rescue growth: in this case the shuttle is available without the toxic consequences of high ROS. Lowering endog-
enous antioxidants by depleting Malic enzyme (hence NADPH)36 was able to block the growth of brat explants. 
This effect of ROS levels on PEPCK depleted explants suggests that the glycerol-3-phophate formed in glycero-
neogenesis is not just used for lipids, but is also used to clear cytoplasmic NADH via the mitochondria. It is still 
poorly understood how PEPCK mediates retrograde carbon flow in the presence of glucose, but high rates of 
PEPCK-mediated glyceroneogenesis are observed in numerous cell types and diets, including cancer cells18, 20, 37, 38.
Our model, then, for effectively blocking the growth of brat tumours is that treatments that decrease the use 
of the glycerol-3-phosphate shuttle (PEPCK-RNAi, hydrazine, GPDH-RNAi, iGP1) are inhibiting growth by pre-
venting the oxidation of cytoplasmic NADH. If the shuttle is available, its activity is significantly limited by the 
production of ROS in redox stressed CIN cells, so treatments that lower ROS levels or that provide an alternative 
source of NAD+ , will tend to rescue tumour growth. By using the appropriate level of PEPCK and GPO1 inhib-
itors we could completely block the growth of these aggressive CIN tumours.
These results emphasize the benefit of starting with an unbiased genetic approach to identifying the key sen-
sitivities of CIN cells. We would not have predicted that PEPCK had a significant role in managing NADH, nor 
that this would be enough to block tumour growth in vivo. It is not surprising that ROS levels can limit tumour 
growth, as they provide a mutagenic advantage to tumours only at the cost of widespread cellular damage. We had 
not previously considered mitochondrial Glycerophosphate Oxidase as a significant source of ROS, however we 
find that in PEPCK brat tumors, the glycerol-3-phosphate shuttle generates growth limiting ROS levels. Blocking 
this pathway lowers ROS levels, but it also prevents PEPCK-inhibited tumours from oxidising NADH, which 
then becomes growth limiting. This trade-off between NADH and ROS suggests that the relationship between 
the glycerol-phosphate shuttle and NADH sources may be a fruitful area of research for combination therapy 
directed at CIN tumors.
Experimental procedures. Oxidative stress analysis. Oxidative damage was analysed in tumor tissue 
using CellRox Green (Invitrogen) according to the manufacturers’ recommendations. Menadione (10 mM), and 
Vitamin E (5 mM) in D22 media were used as a pro-oxidant positive control and anti-oxidant control. Another 
anti-oxidant epigallocatechin gallate-EGCG (10 µM) was used in some experiments. Tissue was dissected in D22 
media then stained in the ROS dye for 20 minutes. Photographs were taken on a Zeiss Axioplan 2 using a fixed 
exposure time for each experiment determined by the positive control (Menadione) treated tissue.
Passaged brat RNAi tissue was dissected and incubated for ROS staining in fly extract media. Fly extract was 
prepared using Schneider’s Drosophila media (0.93 ml), whole fly extract of 200 fly (50 µl), insulin 0.5 mg/1 ml 
(5 µl), penicillin/streptomycin 10,000U/ml (5 µl)39.
Glucose assay. A labelled fluorescent glucose, 2-NBDG (Sigma) was used to detect the uptake of glucose as 
recommended by the supplier. Wing discs were taken from 3rd instar larvae that were still feeding to ensure 
glycolytic metabolism and immediately incubated in 2 μM 2-NBDG for 1.5 h in wing disc culture media39 before 
imaging. Images were taken at 20X with a fixed exposure time for all genotypes and fluorescent intensity was 
measured by using ImageJ software.
Explant and measurement techniques. An injection system was developed using 1.0mm O.D × 0.78mm I.D. 
borosilicate glass capillaries, a capillary holder, a suction tube and a suction apparatus. All the explants were 
done under a dissection microscope, into the ventral side of the fly abdomen13, 40. RFP was used to detect the 
explant presence and its growth. All explants were photographed at 3X under a fluorescence dissecting micro-
scope (Nikon SMZ1500). The number of hosts that survived the transplant and hence contributed to the results 
for each experiment is shown by the number of points on its respective graph.
CIN analysis. CIN was analysed by measuring the rate of anaphase errors. Whole larval brains were fixed using 
3.7% formaldehyde in PBS for 20 minutes, put in 45% and 60% acetic acid in ddH2O for 2 minutes and 45 seconds 
respectively, then squashed onto a cover slip and frozen in liquid nitrogen. Hoechst 33342 (Sigma) at 2 μg/ml 
in PBS was used to stain chromosomes. 50 anaphases were identified per brain and anaphase aberrations were 
scored. CIN analysis for passaged tissue was treated similarly, except all the available anaphases of each explant 
were scored, due to the smaller amount of tissue.
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Cell death analysis. Brain: whole brains were incubated in CellEvent Caspase 3/7 Green (Thermo Fisher) 
according to the recommended protocol. After the treatment, brains were mounted and photographed at 10X on 
a Zeiss Axioplan 2. GFP signals were counted using the Analyse Particle plugin in ImageJ. Passaged tissues were 
treated in a similar way, except the signal was manually counted using the Cell Counter plugin.
Wing discs: wing discs were treated with 1 mM Acridine Orange/PBS stain for three minutes, then briefly 
washed. The discs were mounted in PBS and photographed at 10X on a Zeiss Axoplan 2. The intensity of RFP sig-
nal was measured in ImageJ and normalized relative to the control half of the disc as described3. For ROS analysis 
of wing discs we used CellRox Deep Red (Invitrogen) as described [7].
Drug treatments. Drugs were obtained from Sigma except where noted. For adult fly feeding, drugs were mixed in 
20% sucrose solution. For larvae, drugs were mixed in standard fly food (water, molasses, yeast, glucose, acid-mix, 
agar, semolina, Tegosept) and were given to the host fly when solidified. Drugs used were as follows unless other-
wise noted in figure legends: iGP1 (Vitas-M lab, 1 mM), hydrazine sulphate-HS (10 mM), Metformin-Met (25 mM), 
Ferricyanide-FeCN (0.05 mM), Nicotinamide-Nam (5 mM), Propyl gallate-PG (1 mM). Because hydrazine and met-
formin are relatively non-specific in their targets, they were only used in cases where we could verify the relevance of 
the phenotype by comparison with the RNAi phenotype of the relevant enzyme (PEPCK or GPO1).
Drosophila stocks. Fly stocks were from either the Vienna Drosophila Resource Centre or Bloomington Stock 
Centre, raised at 25 °C, and all treatments were done at room temperature. Gal4 drivers included daughterless-gal4 
and actin-gal4 for brain expression and engrailed-gal4 for wing expression of UAS transgenes. UAS-RFP was 
used as a reporter gene in actin-Gal4 and da-Gal4 driven UAS-bratRNAi tumours. Canton S female flies were 
used as hosts for the CIN tumor explants. Stocks used were as follows; UAS-bratRNAi (34646), UAS-RFP (27391), 
UAS-Mfe2RNAi (v108880), UAS-PEPCKRNAi (v20529), UAS-G6PDRNAi (v101507), UAS-JNKRNAi (v34138), 
UAS-WwoxRNAi (v108307), UAS-MenRNAi (41652), UAS-GpdhRNAi (v29013/GD), UAS-Mdh1RNAi (v41437/GD), 
UAS-mad2RNAi (v47918), UAS-rad21RNAi (v13669), UAS-dicer2. Standard crosses were used to generate the 
genotypes tested, using segregation away from Bl/CyO;TM2/TM6b to combine markers on 2nd and 3rd chro-
mosomes. Where recombination was necessary (en > Gal4 UAS-mad2), the stock was tested for each locus and 
taken through single pair matings to ensure a consistent genotype. The level of depletion by RNAi shown in 
Supplementary Table 1 was measured by qPCR as described (7) using the following primers:
Pepck: (f) CCGTGTGCTGGAATGGATC (r) TTGGGCAGCGAGAAGATCT;
brat: (f) AACCACAACAACTTCAACCTGAC (r) GCGATATATGTAGAGCCGATAGTC;
Gpdh: (f) TCACGACGTGTTACGGTGG (r) CCTCAATGGTTTTTCCAGAAGT;
rp49 control (f) GACGCTTCAAGGGACAGTATCTG (r) AAACGCGGTTCTGCATGAG.
Statistical analysis. In most cases, Dunnett’s multiple comparisons test was used to assess the significance 
of variation in the means of each genotype of test tumour from that observed in the control. A single-tailed t-test 
with Welch’s correction was also used for testing growth relative to a non-growing control. This was only used in 
one case of doubtful significance (the effect of FeCN on brat PEPCK tumor growth), which was also confirmed 
by other tests (e.g. cell death rescue and the effect of nicotinamide). Fisher’s exact tests were used to compare 
proportions (CIN rates). In all graphs, error bars show 95% confidence intervals.
Data availability. All data generated or analysed during this study are included in this published article (and 
its Supplementary Information files).
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